The therapeutic administration of Cav1 scaffold protein might be a worthwhile pursuit, because the loss of Cav1 in the tumor stroma has been previously associated with more aggressive disease and poor patient outcomes in breast cancer, pancreatic cancer, and melanoma (Jia et al., 2014, Qian et al., 2011b, Wu et al., 2011). The gene discussed is CAV1; the disease is neoplasm.